Search alternatives:
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
d decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ppm decrease » _ decrease (Expand Search), pa decreased (Expand Search), 026 decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
d decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
861
Decrease of myopia progression with 0.025% atropine
Published 2018“…<p></p><p>Abstract Purpose: To demonstrate the efficacy of 0.025% atropine eyedrops in myopic children in Brazil for decreasing myopia progression Methods: This was a prospective study with 60 children from Hospital Geral Universitário and Oftalmocenter Santa Rosa in Cuiabá, MT, Brazil, aged between 6 to 12 years, with spherical equivalent refractive error of -1.00 to -6.00 diopters (D) and astigmatism of -1.00 D or smaller. …”
-
862
-
863
-
864
-
865
-
866
-
867
-
868
-
869
-
870
-
871
-
872
-
873
-
874
-
875
A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D
Published 2015“…In addition, the peptide bound the receptor NKG2D, which contains a lectin-like domain that binds Neu5Ac(α2,3)Gal. …”
-
876
Laquinimod prevents EAE and decreases encephalitogenicity of T cells.
Published 2012“…Representative FACS staining is shown including quantification (n = 4–5 mice per group). (E) Laquinimod decreases pathogenic potential of T cells. …”
-
877
Cediranib therapy decreases tumor blood volume.
Published 2013“…<p>(left) After 2–3 days of treatment, a statistically significant (p<0.01) difference in the rCBV (±SEM) was observed between cediranib and control groups with a 16.5±2.2% decrease for cediranib treated animals and a 14.1±2.3% increase for control animals. …”
-
878
-
879
B2 decreases glycolytic intermediates in cells.
Published 2025“…<b>(C)</b> Heatmap of targeted metabolomic data. Each column is a separate biological replicate (n = 5). The box indicates the clustering of decreased downstream glycolytic intermediates in B2-treated cells. …”
-
880